文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非小细胞肺癌患者不同治疗方式后心包积液复发。

Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer.

机构信息

Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, BioMedical Park Hospital, Hsin-Chu, Taiwan.

Department of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, Taipei, Taiwan.

出版信息

ESMO Open. 2022 Feb;7(1):100354. doi: 10.1016/j.esmoop.2021.100354. Epub 2021 Dec 23.


DOI:10.1016/j.esmoop.2021.100354
PMID:34953402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8717440/
Abstract

BACKGROUND: Lung cancer with related pericardial effusion is not rare. Intervention is a crucial step for symptomatic effusion. It is unknown, however, whether the different invasive interventions for pericardial effusion result in different survival outcomes. This study analyzed the clinical characteristics and prognostic factors for patients with non-small-cell lung cancer (NSCLC) who have undergone different procedures. METHODS: From January 2006 to June 2018, we collected data from patients with NSCLC who have received invasive intervention for pericardial effusions. The patients were divided into three categories: simple pericardiocentesis, balloon pericardiotomy, and surgical pericardiectomy. Kaplan-Meier curve and log-rank test were used to analyze the pericardial effusion recurrence-free survival (RFS) and overall survival (OS). RESULTS: A total of 244 patients were enrolled. Adenocarcinoma (83.6%) was the major NSCLC subtype. Invasive intervention, including simple pericardiocentesis, balloon pericardiotomy, and surgical pericardiectomy, had been carried out on 52, 170, and 22 patients, respectively. The 1-year RFS rates in simple pericardiocentesis, balloon pericardiotomy, and surgical pericardiectomy were 19.2%, 31.2%, and 31.8%, respectively (P = 0.128), and the median RFS was 1.67, 5.03, and 8.32 months, respectively (P = 0.008). There was no significant difference in OS, however, with the median OS at 1.67, 6.43, and 8.32 months, respectively (P = 0.064). According to the multivariable analysis, the gravity in pericardial fluid analysis, receiving systemic therapy after pericardial effusion, and the time period from stage IV lung cancer to the presence of pericardial effusion were independent prognostic factors for pericardial effusion RFS and OS. CONCLUSIONS: Patients who have undergone simple pericardiocentesis alone for the management of NSCLC-related pericardial effusion have lower 1-year RFS rates than those who have undergone balloon pericardiotomy and surgical pericardiectomy. Therefore, balloon pericardiotomy and surgical pericardiectomy should be carried out for patients with NSCLC-related pericardial effusion if tolerable.

摘要

背景:肺癌合并心包积液并不罕见。对于有症状的心包积液,介入治疗是关键步骤。然而,尚不清楚不同的心包积液介入治疗是否会导致不同的生存结果。本研究分析了接受不同介入程序的非小细胞肺癌(NSCLC)患者的临床特征和预后因素。

方法:本研究从 2006 年 1 月至 2018 年 6 月收集了接受心包积液介入治疗的 NSCLC 患者的数据。患者被分为三组:单纯心包穿刺、球囊心包切开术和心包切除术。采用 Kaplan-Meier 曲线和对数秩检验分析心包积液无复发生存(RFS)和总生存(OS)。

结果:共纳入 244 例患者。腺癌(83.6%)是主要的 NSCLC 亚型。包括单纯心包穿刺、球囊心包切开术和心包切除术在内的介入治疗分别在 52、170 和 22 例患者中进行。单纯心包穿刺、球囊心包切开术和心包切除术的 1 年 RFS 率分别为 19.2%、31.2%和 31.8%(P=0.128),中位 RFS 分别为 1.67、5.03 和 8.32 个月(P=0.008)。然而,OS 无显著差异,中位 OS 分别为 1.67、6.43 和 8.32 个月(P=0.064)。根据多变量分析,心包液分析的严重程度、心包积液后接受全身治疗以及从 IV 期肺癌到心包积液出现的时间是心包积液 RFS 和 OS 的独立预后因素。

结论:单独接受单纯心包穿刺治疗 NSCLC 相关心包积液的患者 1 年 RFS 率低于接受球囊心包切开术和心包切除术的患者。因此,如果耐受,对于 NSCLC 相关心包积液患者应进行球囊心包切开术和心包切除术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/d9e0dd00aa74/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/7f8703db3751/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/f11634527ae7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/607efc0c9b11/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/d9e0dd00aa74/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/7f8703db3751/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/f11634527ae7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/607efc0c9b11/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9c/8717440/d9e0dd00aa74/gr4.jpg

相似文献

[1]
Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer.

ESMO Open. 2022-2

[2]
Primary percutaneous balloon pericardiotomy for malignant pericardial effusion.

Catheter Cardiovasc Interv. 2008-3-1

[3]
Percutaneous balloon pericardiotomy as the initial and definitive treatment for malignant pericardial effusion.

Rev Esp Cardiol (Engl Ed). 2013-5

[4]
Technical and prognostic outcomes of double-balloon pericardiotomy for large malignancy-related pericardial effusions.

Chest. 2002-9

[5]
Percutaneous balloon pericardiotomy: Treatment of choice in patients with advanced oncological disease and severe pericardial effusion.

Cardiovasc Revasc Med. 2017

[6]
Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy.

Am J Cardiol. 2013-7-2

[7]
Evaluation of Safety and Feasibility of Percutaneous Balloon Pericardiotomy in Hemodynamically Significant Pericardial Effusion (Review of 10-Years Experience in Single Center).

J Interv Cardiol. 2015-10

[8]
Percutaneous balloon pericardiotomy for patients with malignant pericardial effusion including three malignant pleural mesotheliomas.

Angiology. 2001-5

[9]
Percutaneous balloon pericardiotomy in a patient with end stage renal disease with recurrent pericardial effusion & pericardial tamponade.

Indian Heart J. 2010

[10]
Percutaneous balloon pericardiotomy for the treatment of infected pericardial effusion with tamponade.

J Invasive Cardiol. 2006-7

引用本文的文献

[1]
Cardiac Tamponade as the Initial Presentation of Squamous Cell Carcinoma of the Lung: A Case Report and Literature Review.

J Investig Med High Impact Case Rep. 2025

[2]
CT-Based Pericardial Composition Change as an Imaging Biomarker for Radiation-Induced Cardiotoxicity.

Cancers (Basel). 2025-8-13

[3]
Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.

JACC CardioOncol. 2025-6

[4]
Malignant Pericardial Effusion Presenting as a Sequela of Lung Adenocarcinoma.

Cureus. 2024-3-30

[5]
Cardiovascular comorbidities and their prognostic value in small cell lung cancer patients with chemoradiotherapy.

Clin Transl Oncol. 2024-6

[6]
Management of Pericardial Effusion in Patients With Solid Tumor: An Algorithmic, Multidisciplinary Approach Results in Reduced Mortality After Paradoxical Hemodynamic Instability.

Ann Surg. 2024-1-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索